The anti-CD52 monoclonal antibody alemtuzumab is another intuitively attractive option for in-vivo T-cell depletion in CLL, given its activity as both a therapeutic for CLL and a GVHD prophylaxis agent (108–113). This evidence concerns the gene CD52 and B-cell chronic lymphocytic leukemia.